Oral Anti-Amyloid Shows Disease-Modifying Potential

Results of a phase 2 study demonstrate potential Alzheimer's disease –modifying effects of an investigational oral anti-amyloid agent, represented by positive changes in plasma and imaging biomarkers of AD pathology.

"The several-fold greater reduction on the p-tau181 biomarker in plasma compared to plaque-clearing anti-amyloid antibodies, combined with preservation of brain hippocampal volume and their positive correlations with cognitive benefits, further validate the disease-modifying effects of ALZ-801 in Alzheimer's patients," Hey added.Phase 3 Trial Underway

The mean age of the cohort was 69 years, and 51% are women; 70% have mild cognitive impairment, and 30% have mild AD. The mean Mini-Mental State Examination score for the cohort was 26.0. Roughly half are taking a cholinesterase inhibitor. Composite cognitive Z-score improved significantly at 13 and 26 weeks and remained above baseline at 52 weeks in comparison with matched ADNI controls."These are very promising data," Hey told conference attendees.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Experimental Drug Significantly Slows Alzheimer's: StudyThe investigational drug donanemab significantly slowed the decline of Alzheimer's patients' ability to think clearly and go about daily tasks in a large study of adults with early signs of the disease, according to early results.
Source: WebMD - 🏆 709. / 51 Read more »